Your Global Leader in Stem Cell Market Research
Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged. Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).
Both graphs below reveal the iPSC market is expanding. [Read more…]
Pompano Beach, FL, March 13, 2018 — BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, announced today the addition of Dr. Felix Amon, who will consult BSEM with Pharmaceutical Business Development.
[Read more…]
Perinatal stem cells are those derived right before or after birth. They include those derived from the umbilical cord blood and tissue, placental blood and tissue, and the amniotic tissue and amniotic fluid.
However, when stem cells were first identified, only two types of stem cells were described, adult stem cells and embryonic stem cells. The reason a diverse range of stem cell types now exist is that human embryonic stem cells (hESCs) have become further characterized, the diversity of adult stem cell types has substantially expanded and induced pluripotent stem cells (iPSCs) have since been discovered.
Now, researchers debate the number of stem cells in existence, because the number depends on whether stem cells are characterized functionally (for example, neural stem cells, mesenchymal stem cells, and hematopoietic stem cells) or characterized by source tissue (for example, cord blood stem cells, dental pulp stem cells, and amniotic stem cells).
What is clear is that a wide range of stem cell types now exists, which has added substantial complexity to the stem cell landscape.
[Read more…]
Wow, this is a big moment for the stem cell community. We officially crossed 300,000 stem cell publications released to PubMed.gov.
PubMed is a service of the U.S. National Library of Medicine and NIH that comprises more than 27 million citations for biomedical literature.[1] It is the largest and comprehensive global database that exists for scientific publications. [Read more…]
HOLLISTON, Mass., Aug. 7, 2017 /PRNewswire/ — Biostage Inc., (Nasdaq: BSTG), (“Biostage” or the “Company”), a biotechnology company developing bioengineered organ implants to treat cancer, congenital abnormalities and other life-threatening conditions of the esophagus, bronchus and trachea, today announced the use of Biostage’s Cellspan Esophageal Implant product candidate in a patient at a major U.S. hospital via an FDA-approved single-use expanded access application.
